Relationship Between Tramadol Response and Cancer Cachexia: A Retrospective Cohort Study

Area of Science:

• Oncology
• Pain Management
• Clinical Pharmacology

Background:

• Interleukin-6 (IL-6) is implicated in cancer pain and cachexia.
• Previous reports suggest higher IL-6 levels correlate with insufficient tramadol pain relief.
• The relationship between cancer cachexia and tramadol nonresponse remains unclear.

Purpose of the Study:

• To investigate the association between cancer cachexia and tramadol treatment response in patients with cancer pain.

Main Methods:

• Retrospective cohort study of cancer patients treated with tramadol for mild to moderate pain (January 2016 - June 2019).
• Nonresponse defined as <20% pain reduction within 7 days.
• Univariate and multivariate logistic regression analyses were used to assess predictors of nonresponse, including cancer cachexia.

Main Results:

• Cancer cachexia was significantly associated with tramadol nonresponse in univariate analysis (OR: 6.04).
• Higher white blood cell counts and lower body mass index were also associated with nonresponse.
• Multivariate analysis confirmed cancer cachexia as the sole significant predictor of tramadol nonresponse (OR: 5.27).

Conclusions:

• Cancer cachexia is a significant factor associated with poor response to tramadol in patients experiencing cancer pain.
• This finding highlights the need to consider cachexia status when managing pain in cancer patients.